RxDoctor Payments Data

Sean Tirney, MD

Urology · Daytona Beach, FLNPI 1063484848

Payments from drug & device makers

$2,268in general payments, 2019–2025

Across 57 payments — averaging $39.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$940
  • Boston Scientific$366
  • Calyxo, Inc.$301
  • Sumitomo Pharma America, Inc.$74
  • Medtronic$60
  • Urogen Pharma, Inc.$58
  • plus $470 from 17 others

What the payments were for

  • Travel & lodging$61927%
  • Food & beverage$1,61471%
  • Education$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,268 in reported general payments places this provider in the 35th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$80,380
Medicare patients
321
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron67$49,728
Tamsulosin Hcl774$16,301
Trospium Chloride272$12,751
Tolterodine Tartrate74$5,152
Dutasteride130$3,663
Oxybutynin Chloride173$2,711
Finasteride161$2,440
Potassium Citrate ErPotassium Citrate34$1,521
Tolterodine Tartrate ErTolterodine Tartrate15$1,238
Alfuzosin Hcl ErAlfuzosin Hcl33$687
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim62$594
Solifenacin Succinate37$582
Doxazosin Mesylate34$536
Terazosin Hcl17$515
Oxycodone Hcl63$506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$53$49,72867 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 935 urology providers in Florida.

Other urology in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →